Abiopharma

🔍 Freeman Chris (Executive)

Company: Guardant Health, Inc. (GH)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 35,412 shares of Common Stock at $110.49 per share (Direct)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 100,786.00 | transaction_form_type: 4
• Acquired 28,193 shares of Common Stock at $28.37 per share (Direct)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 128,979.00 | transaction_form_type: 4
• Sold 3,463 shares of Common Stock at $167.3805 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 125,516.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 7,365 shares of Common Stock at $168.7909 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 118,151.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 35,364 shares of Common Stock at $169.6337 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 82,787.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 17,413 shares of Common Stock at $170.2407 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 65,374.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 35,412 shares of Stock Option (Right to Buy) at $110.49 per share (Derivative)
  Date: 2026-08-10 | Code: M | Expires: 2031-08-02 | equity_swap_involved: 0 | shares_owned_after: 3,620.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 28,193 shares of Stock Option (Right to Buy) at $28.37 per share (Derivative)
  Date: 2026-08-10 | Code: M | Expires: 2033-12-13 | equity_swap_involved: 0 | shares_owned_after: 1,668.00 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.12 to $167.8325. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.185 to $169.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.195 to $170.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.20 to $170.67. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F5: This represents a stock option award granted on August 3, 2021 that vested over a four-year period and is now 100% vested.
• F6: This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.